Indications Fluibron is a syrup that acts as a mucolytic on acute respiratory diseases, making the mucus more fluid and easier to eliminate. Composition Fluibron Active ingredient 5 ml of syrup contain ambroxol hydrochloride 15 mg; Excipients : Sorbitol 1.5 g Methyl p-hydroxybenzoate 0.005 g Propyl p-hydroxybenzoate 0.0004 g Dosage and method of use Adults : initially 10 ml 3 times a day, then 5 ml 3 times a day. Children from two to five years: 2.5 ml 3 times a day. Children over five years : 5 ml 3 times a day. At the beginning of the treatment the dose can be increased or even doubled in the opinion of the doctor. The enclosed measuring cup has graduated marks at 10ml, 5ml and 2.5ml. Warnings Fluibronit should be administered with caution in patients with peptic ulcer. Extremely rare cases of severe skin lesions such as Stevens – Johnson syndrome and toxic epidermal necrolysis (TEN) have been reported in temporary association with the administration of expectorants such as ambroxol hydrochloride. Most of these cases can be explained by the severity of the patient's underlying disease and / or by concomitant therapy. Also, during the initial phase of Stevens – Johnson syndrome or TEN, patients may experience nonspecific flu-like prodromes such as fever, body aches, rhinitis, cough and sore throat. Because of these misleading nonspecific flu-like prodromes, symptomatic treatment with cough and cold medicines may be instituted. Therefore, if new lesions of the skin or mucous membranes occur, it is necessary to consult a doctor immediately and to stop treatment with ambroxol hydrochloride as a precaution. In the presence of mild or moderate renal insufficiency,Fluibron should only be used after consulting your doctor. As with any medicinal product with hepatic metabolism followed by renal elimination, accumulation of the metabolites of ambroxol generated in the liver may occur in severe renal insufficiency. The syrup formulation also contains parahydroxybenzoates which can cause allergic reactions (including type Contraindications Hypersensitivity to the active substance or to any of the excipients present. Severe hepatic and / or renal disorders. The medicine is contraindicated in children under 2 years of age. delayed). Fluibron in Pregnancy and Lactation Ambroxol hydrochloride crosses the placental barrier. Animal studies have shown no direct or indirect harmful effects on pregnancy, embryonal / fetal development, parturition or postnatal development. Clinical studies and extensive clinical experience after the 28th week of pregnancy did not show any evidence of harmful effects on the fetus. However, it is recommended to observe the usual precautions regarding the use of medicines during pregnancy. Particularly during the first trimester, the use of Fluibron is not recommended. Ambroxol hydrochloride is secreted in breast milk. Although no adverse effects on infants are anticipated, the use of Fluibron is not recommended in nursing mothers. Interactions Following the administration of ambroxol the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been observed. Side effects At the recommended doses the medicine is normally well tolerated. Format 200 ml syrup.